HaematologicaPub Date : 2026-11-12DOI: 10.3324/haematol.2026.301728
Ilja Kalashnikov, Veronica Russell, Rachel Kositsky, Leonardo P A Biral, Panu Kovanen, Johannes Dunkel, Marja-Liisa Karjalainen-Lindsberg, Annika Pasanen, Devang Thakkar, Jean L Koff, David Jaye, Sarah Ondrejka, Eric D Hsi, Emily F Mason, Ridas Juskevicius, Cassandra Love, Jennifer R Shingleton, Elizabeth Thacker, Lanie Happ, Clay Parker, Tushar Dave, Mette Ølgod Pedersen, Magdalena Czader, Jiehao Zhou, Dennis O'Malley, Mina Xu, Andrew Evans, Chee Leong Cheng, Matthew McKinney, Chad M McCall, Eric Tse, Rex Au Yeung, Yasodha Natkunam, Abner Louissaint, Jennifer Chapman, Catalina Amador, Amy Chadburn, Yuri Fedoriw, Amir Behdad, Carlos Galvez, Payal Sojitra, Andrew Evens, Kikkeri N Naresh, Sandeep S Dave, Sirpa Leppä
{"title":"Transcriptional landscape of nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich large B-cell lymphoma: tumor microenvironment and checkpoint genes.","authors":"Ilja Kalashnikov, Veronica Russell, Rachel Kositsky, Leonardo P A Biral, Panu Kovanen, Johannes Dunkel, Marja-Liisa Karjalainen-Lindsberg, Annika Pasanen, Devang Thakkar, Jean L Koff, David Jaye, Sarah Ondrejka, Eric D Hsi, Emily F Mason, Ridas Juskevicius, Cassandra Love, Jennifer R Shingleton, Elizabeth Thacker, Lanie Happ, Clay Parker, Tushar Dave, Mette Ølgod Pedersen, Magdalena Czader, Jiehao Zhou, Dennis O'Malley, Mina Xu, Andrew Evans, Chee Leong Cheng, Matthew McKinney, Chad M McCall, Eric Tse, Rex Au Yeung, Yasodha Natkunam, Abner Louissaint, Jennifer Chapman, Catalina Amador, Amy Chadburn, Yuri Fedoriw, Amir Behdad, Carlos Galvez, Payal Sojitra, Andrew Evens, Kikkeri N Naresh, Sandeep S Dave, Sirpa Leppä","doi":"10.3324/haematol.2026.301728","DOIUrl":"https://doi.org/10.3324/haematol.2026.301728","url":null,"abstract":"<p><p>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B-cell malignancy with an indolent course, yet some cases relapse or transform to Tcell/ histiocyte-rich large B-cell lymphoma (THRLBCL). Biological factors underlying poor outcomes in NLPHL are largely unknown, and the relationship between THRLBCL and untransformed NLPHL has not been systematically defined. We analyzed 178 NLPHL and 22 THRLBCL cases using whole-transcriptome RNA sequencing and clinical data. NLPHL patients were younger, had limited-stage disease, and better outcomes than THRLBCL patients. Variant immuno-architectural patterns (IAP) in NLPHL showed THRLBCL-like transcriptional profiles, especially with splenic involvement and high Lymphocyte-Predominant International Prognostic Score (LP-IPS). In-silico deconvolution of the tumor microenvironment (TME) revealed B-cell enrichment in classic NLPHL, intermediate profiles in variant NLPHL, and increased activated CD4+ and CD8+ T-cells and macrophages in THRLBCL. Higher follicular helper T-cell content was associated with shorter event-free survival in an exploratory analysis. NLPHL cases showed strong B-cell and T-helper signatures, whereas THRLBCL cases were enriched for macrophage and cytotoxic T-cell pathways and expressed higher immune checkpoint genes, suggesting an immunosuppressive TME. Signatures defined a spectrum from classic to variant NLPHL and THRLBCL. External validation in independent cohorts reproduced this gradient, supporting a continuous microenvironmental spectrum spanning NLPHL and THRLBCL.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2026-11-12DOI: 10.3324/haematol.2026.302282
Jiahuan Li, Wenya Li
{"title":"Functional DNase assessment in posttransplant lung injury. Comment on: \"Neutrophil extracellular traps and DNase I levels in the bronchoalveolar lavage fluid of children with pulmonary injury after allogeneic hematopoietic stem cell transplantation: a TRANSPIRE study\".","authors":"Jiahuan Li, Wenya Li","doi":"10.3324/haematol.2026.302282","DOIUrl":"https://doi.org/10.3324/haematol.2026.302282","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to Comment on: \"Risk factors and their contributions to prognosis in multiple myeloma\".","authors":"Tae-Hoon Chung, Jia Geng Chang, Tze King Tan, Wee Joo Chng","doi":"10.3324/haematol.2026.302249","DOIUrl":"https://doi.org/10.3324/haematol.2026.302249","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2026-11-12DOI: 10.3324/haematol.2026.301890
Tugce Guel, Simon Fietz, Emma Eichler, Natalija Novak, Ruth Flümann, Barbara Eichhorst, Michael Hallek, Matthias Zipfel, Joerg Wenzel, Jana Knuever
{"title":"Paraneoplastic spongiotic dermatitis associated with progression to treatment-requiring chronic lymphocytic leukemia.","authors":"Tugce Guel, Simon Fietz, Emma Eichler, Natalija Novak, Ruth Flümann, Barbara Eichhorst, Michael Hallek, Matthias Zipfel, Joerg Wenzel, Jana Knuever","doi":"10.3324/haematol.2026.301890","DOIUrl":"https://doi.org/10.3324/haematol.2026.301890","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2026-11-12DOI: 10.3324/haematol.2026.301866
Regina Ferthio, Ximena Jordan Bruno, Alfred L Garfall, Adam D Cohen, Shivani Kapur, Catherine E Lai, Selina M Luger, Edward A Stadtmauer, Dan T Vogl, Adam Waxman, Sandra P Susanibar-Adaniya
{"title":"Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.","authors":"Regina Ferthio, Ximena Jordan Bruno, Alfred L Garfall, Adam D Cohen, Shivani Kapur, Catherine E Lai, Selina M Luger, Edward A Stadtmauer, Dan T Vogl, Adam Waxman, Sandra P Susanibar-Adaniya","doi":"10.3324/haematol.2026.301866","DOIUrl":"https://doi.org/10.3324/haematol.2026.301866","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2026-11-05DOI: 10.3324/haematol.2026.301319
Fanny Asbaghi, Erik Håkansson, Jakob Hofvander, Yuhong Ning, Yuan Xue, Tierney Philips, Vladimir Lazarevic, Christer Nilsson, Sören Lehmann, Samuel Levy, Gunnar Juliusson, Ravindra Majeti, Niklas Landberg
{"title":"Distinct clinical and molecular profiles of acute myeloid leukemia defined by mutations in <i>IDH1</i>, <i>IDH2</i>, and <i>TET2</i>.","authors":"Fanny Asbaghi, Erik Håkansson, Jakob Hofvander, Yuhong Ning, Yuan Xue, Tierney Philips, Vladimir Lazarevic, Christer Nilsson, Sören Lehmann, Samuel Levy, Gunnar Juliusson, Ravindra Majeti, Niklas Landberg","doi":"10.3324/haematol.2026.301319","DOIUrl":"https://doi.org/10.3324/haematol.2026.301319","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous disease driven by recurring somatic mutations, frequently affecting genes involved in epigenetic regulation. Mutations in IDH1, IDH2, and TET2 are largely mutually exclusive and thought to converge on a shared pathway by impairing TET-mediated DNA demethylation, either directly through loss of TET2 activity or indirectly through the accumulation of the oncometabolite (R)-2-hydroxyglutarate (2-HG) in IDH1- and IDH2-mutant AML. Whether this biochemical convergence translates into similar disease biology remains unclear. Here, we analyzed AML defined by mutations in IDH1, IDH2, or TET2 using population-based data from the Swedish AML Registry, complemented by transcriptomic and 5-hydroxymethylcytosine (5hmC) profiling of purified blasts from a highly selected subset of primary AML samples. TET2-mutant AML occurred at an older age and was associated with a more pronounced thrombocytopenia, whereas IDH1- and IDH2-mutant AML showed deeper neutropenia and more favorable overall survival, including after adjustment for clinical covariates. Transcriptomic and 5hmC alterations showed only modest concordance, with 5hmC profiles providing clearer separation of the mutational subgroups. TET2-mutant samples showed significant enrichment of the oxidative phosphorylation pathway compared with IDH1- and IDH2-mutant AML. The mutational groups also showed distinct closest normal counterparts among healthy hematopoietic cell populations. Together, these findings demonstrate that IDH1, IDH2, and TET2 mutations define clinically and molecularly distinct subgroups of AML, highlighting the relevance of mutation-specific clinical stratification.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
HaematologicaPub Date : 2026-11-05DOI: 10.3324/haematol.2026.301773
Julian Liebaert, Martin Neumann, Lorenz Bastian, Claudia D Baldus, Monika Brüggemann, Stefan Habringer, Thomas Burmeister, Nicola Gökbuget, Ulrich Keller, Stefan Schwartz
{"title":"Flow cytometric detection of the thymic stromal lymphopoietin receptor reliably identifies <i>CRLF2</i>-rearranged <i>BCR</i>::<i>ABL1</i>-like acute lymphoblastic leukemia.","authors":"Julian Liebaert, Martin Neumann, Lorenz Bastian, Claudia D Baldus, Monika Brüggemann, Stefan Habringer, Thomas Burmeister, Nicola Gökbuget, Ulrich Keller, Stefan Schwartz","doi":"10.3324/haematol.2026.301773","DOIUrl":"https://doi.org/10.3324/haematol.2026.301773","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CD34<sup>+</sup>-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a large cohort study focusing on haploidentical transplantation.","authors":"Yun He, Linwei Shi, Rui Ma, Tingting Han, Yao Chen, Yuanyuan Zhang, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Haixia Fu, Chenhua Yan, Meng Lv, Xiaodong Mo, Yifei Cheng, Yu Wang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Aiming Pang, Yuqian Sun","doi":"10.3324/haematol.2026.301404","DOIUrl":"https://doi.org/10.3324/haematol.2026.301404","url":null,"abstract":"<p><p>Poor graft function (PGF) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). CD34+-selected stem cell boost has shown promise; however, data in the haploidentical setting and after failure of thrombopoietin receptor agonists (TPO-RAs) are limited. Patients who received purified CD34+ boost for refractory PGF after HSCT at two centers were retrospectively analyzed. Outcomes included overall response rate (ORR), graft-versus-host disease (GVHD) and overall survival (OS). Among the 116 evaluable patients, 86.79% (103/116) received haploidentical transplants and 113 (97.4%) had received at least one platelet-stimulating agent, including TPO-RA and/or recombinant human thrombopoietin (rhTPO). The ORR was 67.24% (CR 62.93%, PR 4.31%). The 180-day cumulative recovery rates of neutrophils, hemoglobin, and platelets were 56.7%, 57.1%, and 65.7%, respectively. Active infection at the time of CD34+-selected stem cell boost was the sole independent predictor of lower ORR (OR = 3.786, 95% CI: 1.584-9.048, P = 0.003). The incidence of grade III-IV acute GVHD was 9.48%, and that of moderate-to-severe chronic GVHD was 11.21%. The OS was 64.66%. Responders had a significantly better OS than nonresponders (81.65% vs. 11.67%, P < 0.001). In conclusion, CD34+-selected stem cell boost is safe and highly effective for refractory PGF after allo-HSCT, including in haploidentical recipients and those who have failed TPO-RAs. Active infection at infusion predicts a poor treatment response, and non-responders have a dismal prognosis, underscoring the need for alternative strategies.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}